BCAX
Bicara Therapeutics Inc. Common Stock NASDAQ$22.72
After hrs
$22.85
-1.34%
Mkt Cap $1.2B
52w Low $7.80
90.7% of range
52w High $24.25
50d MA $20.09
200d MA $16.22
P/E (TTM)
-8.6x
EV/EBITDA
-5.3x
P/B
3.0x
Debt/Equity
0.0x
ROE
-34.4%
P/FCF
-8.6x
RSI (14)
—
ATR (14)
—
Beta
-1.23
50d MA
$20.09
200d MA
$16.22
Avg Volume
549.5K
About
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorpor…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.72 | -0.68 | +5.6% | 18.92 | -1.4% | -2.9% | +0.6% | +5.1% | +8.4% | +13.5% | — |
| Nov 10, 2025 | AMC | -0.55 | -0.67 | -21.8% | 13.93 | -0.9% | +5.7% | +7.0% | +2.4% | +6.1% | +8.0% | — |
| Aug 12, 2025 | AMC | -0.54 | -0.50 | +7.4% | 10.47 | +1.5% | +8.2% | +9.0% | +11.2% | +9.6% | +9.9% | — |
| May 13, 2025 | AMC | -0.40 | -0.68 | -70.0% | 13.04 | +1.2% | +5.1% | +11.0% | +11.0% | +16.6% | +15.3% | — |
| Mar 27, 2025 | AMC | -0.31 | -0.39 | -25.8% | 13.40 | -0.1% | +0.0% | -2.8% | -5.5% | -1.0% | -11.7% | — |
| Nov 12, 2024 | AMC | -0.46 | -1.60 | -247.8% | 22.35 | +0.0% | -1.6% | -0.4% | -9.8% | -14.1% | -13.6% | — |
| Sep 13, 2024 | AMC | — | -0.27 | — | 23.41 | -4.6% | +8.5% | +15.6% | +9.9% | +5.1% | +9.4% | — |
| Jun 30, 2024 | AMC | — | -0.27 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.23 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.42 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Citizens | Maintains | Market Outperform → Market Outperform | — | $19.04 | $19.41 | +1.9% | +4.5% | +7.7% | +12.8% | +9.5% | +11.8% |
| Mar 31 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.04 | $19.41 | +1.9% | +4.5% | +7.7% | +12.8% | +9.5% | +11.8% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.04 | $19.41 | +1.9% | +4.5% | +7.7% | +12.8% | +9.5% | +11.8% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $19.04 | $19.41 | +1.9% | +4.5% | +7.7% | +12.8% | +9.5% | +11.8% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.04 | $19.41 | +1.9% | +4.5% | +7.7% | +12.8% | +9.5% | +11.8% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $17.43 | $17.34 | -0.5% | +0.6% | +3.4% | -4.2% | -3.9% | -4.1% |
| Nov 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.93 | $13.80 | -0.9% | +5.7% | +7.0% | +2.4% | +6.1% | +8.0% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.63 | $11.63 | +0.0% | +1.8% | -2.7% | +3.5% | +3.4% | +2.4% |
| May 23 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $15.66 | $11.65 | -25.6% | -40.8% | -36.3% | -39.6% | -39.7% | -40.9% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.47 | $13.77 | -4.8% | +0.0% | +5.1% | +3.9% | +0.8% | +8.2% |
Recent Filings
8-K
Unknown — 8-K Filing
Bicara advanced its lead cancer drug ficerafusp alfa into Phase 3 with an optimized dosing schedule, potentially improving patient compliance and commercial viability; interim data in mid-2027 will determine success probability.
Mar 30
8-K
Bicara Therapeutics Inc. -- 8-K Filing
Bicara Therapeutics issued pre-funded warrants exercisable at $0.0001 per share, allowing immediate cashless exercise, providing investors with nearly certain conversion rights to common stock.
Feb 26
8-K · 8.01
!! High
Bicara Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Bicara Therapeutics announced that ficerafusp alfa at 2000mg every-two-weeks showed strong efficacy in head-and-neck cancer patients, supporting potential for less frequent dosing schedules.
Feb 19
Data updated apr 24, 2026 8:50pm
· Source: massive.com